Angibaud P - Search Results

1

4-methyl-1,2,4-triazol-3-yl heterocycle as an alternative to the 1-methylimidazol-5-yl moiety in the farnesyltransferase inhibitor ZARNESTRA.

Angibaud P, Saha AK, Bourdrez X, End DW, Freyne E, Lezouret P, Mannens G, Mevellec L, Meyer C, Pilatte I, Poncelet V, Roux B, Smets G, Van Dun J, Venet M, Wouters W. Angibaud P, et al. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4361-4. doi: 10.1016/j.bmcl.2003.09.043. Bioorg Med Chem Lett. 2003. PMID: 14643326

2

5-imidazolyl-quinolinones, -quinazolinones and -benzo-azepinones as farnesyltransferase inhibitors.

Angibaud P, Bourdrez X, Devine A, End DW, Freyne E, Ligny Y, Muller P, Mannens G, Pilatte I, Poncelet V, Skrzat S, Smets G, Van Dun J, Van Remoortere P, Venet M, Wouters W. Angibaud P, et al. Bioorg Med Chem Lett. 2003 May 5;13(9):1543-7. doi: 10.1016/s0960-894x(03)00180-x. Bioorg Med Chem Lett. 2003. PMID: 12699751

3

Farnesyl protein transferase inhibitor ZARNESTRA R115777 - history of a discovery.

Venet M, End D, Angibaud P. Venet M, et al. Among authors: angibaud p. Curr Top Med Chem. 2003;3(10):1095-102. doi: 10.2174/1568026033452050. Curr Top Med Chem. 2003. PMID: 12769710 Review.

4

Substituted azoloquinolines and -quinazolines as new potent farnesyl protein transferase inhibitors.

Angibaud P, Bourdrez X, End DW, Freyne E, Janicot M, Lezouret P, Ligny Y, Mannens G, Damsch S, Mevellec L, Meyer C, Muller P, Pilatte I, Poncelet V, Roux B, Smets G, Van Dun J, Van Remoortere P, Venet M, Wouters W. Angibaud P, et al. Bioorg Med Chem Lett. 2003 Dec 15;13(24):4365-9. doi: 10.1016/j.bmcl.2003.08.080. Bioorg Med Chem Lett. 2003. PMID: 14643327

5

Impact on farnesyltransferase inhibition of 4-chlorophenyl moiety replacement in the Zarnestra series.

Angibaud P, Mevellec L, Meyer C, Bourdrez X, Lezouret P, Pilatte I, Poncelet V, Roux B, Merillon S, End DW, Van Dun J, Wouters W, Venet M. Angibaud P, et al. Eur J Med Chem. 2007 May;42(5):702-14. doi: 10.1016/j.ejmech.2006.12.007. Epub 2007 Jan 9. Eur J Med Chem. 2007. PMID: 17316920

6

Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.

Angibaud P, Van Emelen K, Decrane L, van Brandt S, Ten Holte P, Pilatte I, Roux B, Poncelet V, Speybrouck D, Queguiner L, Gaurrand S, Mariën A, Floren W, Janssen L, Verdonck M, van Dun J, van Gompel J, Gilissen R, Mackie C, Du Jardin M, Peeters J, Noppe M, Van Hijfte L, Freyne E, Page M, Janicot M, Arts J. Angibaud P, et al. Bioorg Med Chem Lett. 2010 Jan 1;20(1):294-8. doi: 10.1016/j.bmcl.2009.10.118. Epub 2009 Oct 30. Bioorg Med Chem Lett. 2010. PMID: 19906529

7

Discovery of pyrimidyl-5-hydroxamic acids as new potent histone deacetylase inhibitors.

Angibaud P, Arts J, Van Emelen K, Poncelet V, Pilatte I, Roux B, Van Brandt S, Verdonck M, De Winter H, Ten Holte P, Marien A, Floren W, Janssens B, Van Dun J, Aerts A, Van Gompel J, Gaurrand S, Queguiner L, Argoullon JM, Van Hijfte L, Freyne E, Janicot M. Angibaud P, et al. Eur J Med Chem. 2005 Jun;40(6):597-606. doi: 10.1016/j.ejmech.2005.01.008. Epub 2005 Mar 3. Eur J Med Chem. 2005. PMID: 15922843

8

Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.

End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P, Venet M, Sanz G, Poignet H, Skrzat S, Devine A, Wouters W, Bowden C. End DW, et al. Among authors: angibaud p. Cancer Res. 2001 Jan 1;61(1):131-7. Cancer Res. 2001. PMID: 11196150

9

JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity.

Arts J, King P, Mariën A, Floren W, Beliën A, Janssen L, Pilatte I, Roux B, Decrane L, Gilissen R, Hickson I, Vreys V, Cox E, Bol K, Talloen W, Goris I, Andries L, Du Jardin M, Janicot M, Page M, van Emelen K, Angibaud P. Arts J, et al. Among authors: angibaud p. Clin Cancer Res. 2009 Nov 15;15(22):6841-51. doi: 10.1158/1078-0432.CCR-09-0547. Epub 2009 Oct 27. Clin Cancer Res. 2009. PMID: 19861438

10

Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.

Perera TPS, Jovcheva E, Mevellec L, Vialard J, De Lange D, Verhulst T, Paulussen C, Van De Ven K, King P, Freyne E, Rees DC, Squires M, Saxty G, Page M, Murray CW, Gilissen R, Ward G, Thompson NT, Newell DR, Cheng N, Xie L, Yang J, Platero SJ, Karkera JD, Moy C, Angibaud P, Laquerre S, Lorenzi MV. Perera TPS, et al. Among authors: angibaud p. Mol Cancer Ther. 2017 Jun;16(6):1010-1020. doi: 10.1158/1535-7163.MCT-16-0589. Epub 2017 Mar 24. Mol Cancer Ther. 2017. PMID: 28341788

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

25 results

Search Page